Anti-inflammatory profile of Paricalcitol (cas 131918-61-1) in kidney transplant recipients
-
Add time:07/26/2019 Source:sciencedirect.com
Background and objectivesParicalcitol (cas 131918-61-1), a selective vitamin D receptor activator, is used to treat secondary hyperparathyroidism in kidney transplant patients. Experimental and clinical studies in non-transplant kidney disease patients have found this molecule to have anti-inflammatory properties. In this exploratory study, we evaluated the anti-inflammatory profile of paricalcitol in kidney-transplant recipients.
We also recommend Trading Suppliers and Manufacturers of Paricalcitol (cas 131918-61-1). Pls Click Website Link as below: cas 131918-61-1 suppliers
Prev:On the mechanism of catalytic alkene oxidation by molecular oxygen and halogenated iron porphyrins
Next:Paricalcitol (cas 131918-61-1) alleviates lipopolysaccharide-induced depressive-like behavior by suppressing hypothalamic microglia activation and neuroinflammation) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Effect of Paricalcitol (cas 131918-61-1) on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism08/02/2019
- Effects of oral Paricalcitol (cas 131918-61-1) therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism08/01/2019
- Paricalcitol (cas 131918-61-1) Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients07/31/2019
- Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol (cas 131918-61-1)07/30/2019
- Perfil antiinflamatorio del Paricalcitol (cas 131918-61-1) en el receptor de trasplante renal07/29/2019
- Vitamin D receptor activation by Paricalcitol (cas 131918-61-1) and insulin resistance in CKD07/28/2019
- Paricalcitol (cas 131918-61-1) alleviates lipopolysaccharide-induced depressive-like behavior by suppressing hypothalamic microglia activation and neuroinflammation07/27/2019